TRENDS

Economic Benefits for Patients, Healthcare Providers Driving Biosimilar Sales Growth as Quality Worries Fade

By Reiji Anasako November 15, 2018
Biosimilars are finally taking off. Japan’s first Enbrel (etanercept) follow-on has been hit by beyond-expected demand, while Sandoz/Kyowa Hakko Kirin’s Rituxan (rituximab) copy, also the country’s first, is likely to enjoy an upswing in its guidance. One thing they have…

To read the full story

TRENDS

Takeda Pharmaceutical CEO Christophe Weber highlighted the importance of gaining a strong foothold in the world’s largest pharma market at…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…

By Yoshinori Sagehashi

Daiichi Sankyo and GlaxoSmithKline recently announced that they have agreed to dissolve their joint venture company, Japan Vaccine. The failure of this model of joint venture between a major Japanese and foreign drug maker in just six years is disappointing.Over…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…